WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, November 24, 2004

Hide?	Set Name	Query	Hit Count
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L12	6407062.pn.	1
☐	L11	5708136.pn.	1
☐	L10	5420263.pn.	1
☐	L9	5411860	15
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L7	L6 not l3	6
☐	L6	L5 with human	19
☐	L5	(mouse or murine)double minute	52
☐	L3	L1 with human	13
☐	L1	mouse double minute	33

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 13 returned.

☐ 1. Document ID: US 20040191783 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 13 File: PGPB Sep 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040191783
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040191783 A1

TITLE: Low density micro-array analysis in human breast cancer

PUBLICATION-DATE: September 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leclercq, Guy	Bruxelles		BE	
Remacle, Jose	Malonne		BE	
Lacroix, Marc	Baelen		BE	
Zammatteo, Nathalie	Gelbressee		BE	
de Longueville, Francoise	Natoye		BE	

US-CL-CURRENT: 435/6; 435/287.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 2. Document ID: US 20040170653 A1

L3: Entry 2 of 13 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040170653
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040170653 A1

TITLE: Tumour peptide antigen produced from human mdm2 proto-oncogene

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stanislawski, Thomas	Jugenheim		DE	
Theobald, Matthias	Mainz-Kastel		DE	

US-CL-CURRENT: 424/277.1; 514/44, 530/350, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20040132108 A1

L3: Entry 3 of 13 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132108
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132108 A1

TITLE: Screening methods and agents

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hupp, Theodore Robert	Dundee		GB	
Dornan, David	Dundee		GB	

US-CL-CURRENT: 435/7.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20040072769 A1

L3: Entry 4 of 13 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072769
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072769 A1

TITLE: Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yin, James Qinwei	Boston	MA	US	

US-CL-CURRENT: 514/44; 435/6, 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20040023207 A1

L3: Entry 5 of 13 File: PGPB Feb 5, 2004

h e b b g e e e f e c ef b e

PGPUB-DOCUMENT-NUMBER: 20040023207
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023207 A1

TITLE: Assays for drug discovery based on microcompetition with a foreign polynucleotide

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Polansky, Hanan	Rochester	NY	US	

US-CL-CURRENT: 435/5; 435/455, 435/456, 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 6. Document ID: US 20040023206 A1

L3: Entry 6 of 13 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023206
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023206 A1

TITLE: Methods for chronic disease diagnosis based on microcompetition with a foreign polynucleotide

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Polansky, Hanan	Rochester	NY	US	

US-CL-CURRENT: 435/5; 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 7. Document ID: US 20040022764 A1

L3: Entry 7 of 13 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040022764
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040022764 A1

TITLE: Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Polansky, Hanan	Rochester	NY	US	

US-CL-CURRENT: 424/93.2; 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 8. Document ID: US 20030104358 A1

L3: Entry 8 of 13 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104358
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104358 A1

TITLE: Diagnosis methods based on microcompetition for a limiting GABP complex

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Polansky, Hanan	Rochester	NY	US	

US-CL-CURRENT: 435/5; 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 9. Document ID: US 20030069199 A1

L3: Entry 9 of 13 File: PGPB Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030069199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030069199 A1

TITLE: Treatment methods based on microcompetition for a limiting GABP complex

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Polansky, Hanan	Rochester	NY	US	

US-CL-CURRENT: 514/44; 424/186.1, 424/93.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 10. Document ID: US 20030059791 A1

h e b b g e e e f e c ef b e

L3: Entry 10 of 13 File: PGPB Mar 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030059791
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030059791 A1

TITLE: Method for evaluating DNA probes position on substrate

PUBLICATION-DATE: March 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rokutan, Kazuhito	Osaka		JP	
Tomita, Hiroyuki	Tachikawa		JP	
Saito, Toshiro	Hatoyama		JP	

US-CL-CURRENT: 435/6; 435/287.2, 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L1 with human	13

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e c ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 11 through 13 of 13 returned.

☐ 11. Document ID: US 20030054387 A1

Using default format because multiple data bases are involved.

L3: Entry 11 of 13 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054387
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054387 A1

TITLE: Metastasis-associated genes

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chen, Jeremy J.W.	Fengyuan City		TW	
Yang, Pan-Chyr	Taipei		TW	
Peck, Konan	Taipei		TW	
Hong, Tse-Ming	Taipei		TW	
Yang, Shuenn-Chen	Taipei		TW	
Wu, Cheng-Wen	Taipei		TW	

US-CL-CURRENT: 435/6; 702/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 12. Document ID: US 20020012927 A1

L3: Entry 12 of 13 File: PGPB Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020012927
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020012927 A1

TITLE: Nucleic acid sequences associated wih aging, particularly skin aging

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burmer, Glenna C.	Seattle	WA	US	
Brown, Joseph P.	Seattle	WA	US	

h e b b cg b cc e

Pritchard, David Seattle WA US

US-CL-CURRENT: 435/6; 435/7.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

13. Document ID: US 5756669 A

L3: Entry 13 of 13 File: USPT May 26, 1998

US-PAT-NO: 5756669
DOCUMENT-IDENTIFIER: US 5756669 A

TITLE: P53-binding polypeptides and polynucleotides encoding same

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L1 with human	13

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b cg b cc e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 15 returned.

☐ 1. Document ID: US 6770627 B1

Using default format because multiple data bases are involved.

L9: Entry 1 of 15 File: USPT Aug 3, 2004

US-PAT-NO: 6770627
DOCUMENT-IDENTIFIER: US 6770627 B1

TITLE: Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p 53

DATE-ISSUED: August 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luke; Richard Wa	Macclesfield			GB
Jewsbury; Philip J.	Macclesfield			GB
Cotton; Ronald	Macclesfield			GB

US-CL-CURRENT: 514/18; 514/19, 514/252.13, 514/254.09, 514/255.01, 530/331, 544/359, 544/373, 544/386, 544/391

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi De

☐ 2. Document ID: US 6613750 B2

L9: Entry 2 of 15 File: USPT Sep 2, 2003

US-PAT-NO: 6613750
DOCUMENT-IDENTIFIER: US 6613750 B2

TITLE: Method of inhibiting cell proliferation using an anti-oncogene protein

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi De

☐ 3. Document ID: US 6399755 B1

L9: Entry 3 of 15 File: USPT Jun 4, 2002

US-PAT-NO: 6399755
DOCUMENT-IDENTIFIER: US 6399755 B1
** See image for Certificate of Correction **

h e b b g e e e f e c ef b e

TITLE: Products for inhibiting expression of human MDM2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

---

☐ 4. Document ID: US 6013786 A

L9: Entry 4 of 15 File: USPT Jan 11, 2000

US-PAT-NO: 6013786
DOCUMENT-IDENTIFIER: US 6013786 A

TITLE: MDM2-specific antisense oligonucleotides

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

---

☐ 5. Document ID: US 5858976 A

L9: Entry 5 of 15 File: USPT Jan 12, 1999

US-PAT-NO: 5858976
DOCUMENT-IDENTIFIER: US 5858976 A
** See image for Certificate of Correction **

TITLE: Methods for inhibiting interaction of human MDM2 and p53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

---

☐ 6. Document ID: US 5858673 A

L9: Entry 6 of 15 File: USPT Jan 12, 1999

US-PAT-NO: 5858673
DOCUMENT-IDENTIFIER: US 5858673 A
** See image for Certificate of Correction **

TITLE: Method for detecting prostate cells

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

---

☐ 7. Document ID: US 5756455 A

L9: Entry 7 of 15 File: USPT May 26, 1998

US-PAT-NO: 5756455
DOCUMENT-IDENTIFIER: US 5756455 A

TITLE: Amplification of human MDM2 gene in human tumors

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

h e b b g e e e f e c ef b e

☐ 8. Document ID: US 5736338 A

L9: Entry 8 of 15 File: USPT Apr 7, 1998

US-PAT-NO: 5736338
DOCUMENT-IDENTIFIER: US 5736338 A

TITLE: Method of diagnosing Neoplastic disease by detecting increased expression of human MDM2 protein

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

☐ 9. Document ID: US 5708136 A

L9: Entry 9 of 15 File: USPT Jan 13, 1998

US-PAT-NO: 5708136
DOCUMENT-IDENTIFIER: US 5708136 A

TITLE: Polypetides which bind to human MDM2

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

☐ 10. Document ID: US 5702903 A

L9: Entry 10 of 15 File: USPT Dec 30, 1997

US-PAT-NO: 5702903
DOCUMENT-IDENTIFIER: US 5702903 A

TITLE: Method and cells for drug identification

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
5411860	15

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e c ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20030152959 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 6 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152959
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152959 A1

TITLE: Method of using estrogen-related receptor alpha (ERRalpha) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRalpha as a therapeutic target for the treatment of breast cancer

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mertz, Janet E.	Madison	WI	US	
Johnston, Stephen D.	Wheaton	IL	US	
Kraus, Richard J.	McFarland	WI	US	
Ariazi, Eric A.	Madison	WI	US	

US-CL-CURRENT: 435/6; 435/7.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20020045192 A1

L7: Entry 2 of 6 File: PGPB Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045192
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020045192 A1

TITLE: Arf and HDM2 interaction domains and methods of use thereof

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kriwacki, Richard	Memphis	TN	US	
Bothner, Brian	Memphis	TN	US	

h e b b g e e e f e c ef b e

Lewis, William Memphis TN US

US-CL-CURRENT: 435/7.1; 514/1, 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 3. Document ID: US 20010018511 A1

L7: Entry 3 of 6 File: PGPB Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018511
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010018511 A1

TITLE: INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LANE, DAVID	FIFE		GB	
BOTTGER, VOLKER	GERMERING		DE	
BOTTGER, ANGELIKA	GERMERING		DE	
PICKSLEY, STEVEN MICHAEL	BRADFORD		GB	
HOCHKEPPEL, HEINZ-KURT	AESCH		CH	
GARCIA-ECHEVERRIA, CARLOS	BASEL		CH	
CHENE, PATRICK	MULHOUSE		FR	
FURET, PASCAL	THANN		FR	

US-CL-CURRENT: 536/24.5; 435/375, 435/377, 435/6, 435/7.1, 530/300, 530/326, 530/327, 530/328, 530/333, 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 4. Document ID: US 6407062 B1

L7: Entry 4 of 6 File: USPT Jun 18, 2002

US-PAT-NO: 6407062
DOCUMENT-IDENTIFIER: US 6407062 B1
**** See image for Certificate of Correction ****

TITLE: ARF-P19, a novel regulator of the mammalian cell cycle

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

---

☐ 5. Document ID: WO 3106707 A1

L7: Entry 5 of 6 File: EPAB Dec 24, 2003

h e b b g e e e f e c ef b e

PUB-NO: WO003106707A1
DOCUMENT-IDENTIFIER: WO 3106707 A1
TITLE: METHOD FOR DETECTING INCREASED SUSCEPTIBILITY TO TUMOURS

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

6. Document ID: WO 2003106707 A1, DE 10228081 A1

L7: Entry 6 of 6 File: DWPI Dec 24, 2003

DERWENT-ACC-NO: 2004-142783
DERWENT-WEEK: 200414

TITLE: Detecting susceptibility to tumors, especially prostatic carcinoma, comprises identifying a specific polymorphism in the human murine-double minute gene

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L6 not L3	6

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e c ef b e

First Hit Previous Doc Next Doc Go to Doc#
End of Result Set

Generate Collection Print

L7: Entry 6 of 6 File: DWPI Dec 24, 2003

DERWENT-ACC-NO: 2004-142783
DERWENT-WEEK: 200414

TITLE: Detecting susceptibility to tumors, especially prostatic carcinoma, comprises identifying a specific polymorphism in the human murine-double minute gene

INVENTOR: BENDZKO, P; HILLEBRAND, T ; KAPPLER, M ; KRUEGER, K ; MEYE, A ; TAUBERT, H ; WIRTH, M

PATENT-ASSIGNEE: INVITEK GES BIOTECHNIK & BIODESIGN MBH (INVIN), BENDZKO P (BENDI), HILLEBRAND T (HILLI), KAPPLER M (KAPPI), KRUEGER K (KRUEI), MEYE A (MEYEI), TAUBERT H (TAUBI), WIRTH M (WIRTI)

PRIORITY-DATA: 2002DE-1028081 (June 18, 2002)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2003106707 A1	December 24, 2003	G	026	C12Q001/68
DE 10228081 A1	January 8, 2004		000	C12Q001/68

DESIGNATED-STATES: CA CN JP US AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO2003106707A1	June 16, 2003	2003WO-EP06306	
DE 10228081A1	June 18, 2002	2002DE-1028081	

INT-CL (IPC): C12 Q 1/68

ABSTRACTED-PUB-NO: WO2003106707A
BASIC-ABSTRACT:

NOVELTY - Detecting susceptibility to tumors by genotyping a nucleic acid sample for presence of the base exchange A to G (GAA to GAG) at position 354 in exon 12 of the human mdm-2 (murine-double-minute) gene, to determine the allelic status at this polymorphic site.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

h e b b g e e e f c e c e ge

(1) therapeutic agent directed against genes that modify pathways in which mdm2 is involved and/or affect the specific polymorphism and associated genes, and act by regulating transcription and translation, as well as influencing their efficiency, particularly by regulating expression;

(2) therapeutic agents similar to those of (1) but directed against human mdm-2 and able to affect the specified polymorphism; and

in vitro and in vivo test systems for detecting the specified polymorphism.

ACTIVITY - Cytostatic. No details of tests for cytostatic activity are given.

MECHANISM OF ACTION - mdm2 is involved in a feed-back loop with the p53 tumor suppressor and also negatively regulates the Rb protein; Gene therapy.

USE - Determining the specified A to G mutation (homozygous or heterozygous) indicates an increased risk of developing tumors and of transmitting this risk to descendants, particularly carcinoma of the prostate (specifically), breast, cervix or ovary. A test system that can detect the polymorphism can be used to investigate diseases in which mdm-2 is implicated, also to develop and test individual, specific therapeutic agents. Agents that act on the mdm-2 gene, or pathways in which it is involved, are potentially useful therapeutically.

ADVANTAGE - The specified polymorphism is a very general marker for increased risk of developing tumors; previously it was known only to be associated with increased risk of sarcoma.

ABSTRACTED-PUB-NO: WO2003106707A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B04 D16 S03
CPI-CODES: B04-E02F; B04-E03F; B04-E05; B04-E09; B04-F01; B04-G01; B04-L01; B04-P0100E; B11-C07A4; B11-C08E; B11-C10A; B12-K04A1; B12-K04A3; B12-K04E; B12-K04F; B14-H01; B14-S03; D05-H09;
EPI-CODES: S03-E14H4;

Previous Doc Next Doc Go to Doc#

```
$%^STN;HighlightOn=  ***;HighlightOff=***  ;

Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1800EXS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS  4  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS  5  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS  6  SEP 27   STANDARDS will no longer be available on STN
 NEWS  7  SEP 27   SWETSCAN will no longer be available on STN
 NEWS  8  OCT 28   KOREAPAT now available on STN
 NEWS  9  NOV 18   Current-awareness alerts, saved answer sets, and current
                   search transcripts to be affected by CERAB, COMPUAB, ELCOM,
                   and SOLIDSTATE reloads

 NEWS EXPRESS  OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:46:04 ON 24 NOV 2004

=> fil .eliz
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.21       0.21

FILE 'MEDLINE' ENTERED AT 18:46:15 ON 24 NOV 2004

FILE 'SCISEARCH' ENTERED AT 18:46:15 ON 24 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'LIFESCI' ENTERED AT 18:46:15 ON 24 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 18:46:15 ON 24 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOSIS' ENTERED AT 18:46:15 ON 24 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 18:46:15 ON 24 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 18:46:15 ON 24 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'NTIS' ENTERED AT 18:46:15 ON 24 NOV 2004

FILE 'ESBIOBASE' ENTERED AT 18:46:15 ON 24 NOV 2004

FILE 'BIOTECHNO' ENTERED AT 18:46:15 ON 24 NOV 2004

FILE 'WPIDS' ENTERED AT 18:46:15 ON 24 NOV 2004


```
=> s (mouse or murine)(2w) double minute
  10 FILES SEARCHED...
L1          1054 (MOUSE OR MURINE)(2W) DOUBLE MINUTE

=> s l1 (5a) human
   9 FILES SEARCHED...
L2           136 L1 (5A) HUMAN

=> s l2 and splice?
L3            17 L2 AND SPLICE?

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             5 DUP REM L3 (12 DUPLICATES REMOVED)

=> d 1-5

L4   ANSWER 1 OF 5     MEDLINE on STN                    DUPLICATE 1
AN   2002053945     MEDLINE
DN   PubMed ID: 11779693
TI   Function and dysfunction of the human oncoprotein MDM2.
AU   Deb Swati Palit
CS   Department of Biochemistry and Molecular Biophysics and the Massey Cancer
     Center, Medical College of Virginia, Virginia Commonwealth University,
     Richmond, VA 23298, USA.. Spdeb@hsc.vcu.edu
NC   CA70712 (NCI)
     CA74172 (NCI)
SO   Frontiers in bioscience : a journal and virtual library, (2002 Jan 1) 7
     d235-43.  Ref: 112
     Journal code: 9709506. ISSN: 1093-4715.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LA   English
FS   Priority Journals
EM   200204
ED   Entered STN: 20020125
     Last Updated on STN: 20020410
     Entered Medline: 20020409

L4   ANSWER 2 OF 5     MEDLINE on STN                    DUPLICATE 2
AN   2002125412     MEDLINE
DN   PubMed ID: 11859876
TI   Overexpression of MDM2 oncoprotein correlates with possession of estrogen
     receptor alpha and lack of MDM2 mRNA   ***splice***   variants in human
     breast cancer.
AU   Hori Masao; Shimazaki Jiro; Inagawa Satoshi; Itabashi Masayuki; Hori
     Mitsuo
CS   Department of Pathology, Ibaraki Prefectural Central Hospital and Cancer
     Center, Japan.. ms-hori@chubyoin.pref.ibaraki.jp
SO   Breast cancer research and treatment, (2002 Jan) 71 (1) 77-83.
     Journal code: 8111104. ISSN: 0167-6806.
CY   Netherlands
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200208
```

ED Entered STN: 20020226
Last Updated on STN: 20020814
Entered Medline: 20020813

L4 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 3
AN 2001444709 MEDLINE
DN PubMed ID: 11494132
TI An alternatively ***spliced*** HDM2 product increases p53 activity by inhibiting HDM2.
AU Evans S C; Viswanathan M; Grier J D; Narayana M; El-Naggar A K; Lozano G
CS Department of Molecular Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, TX 77030, USA.
NC CA34936 (NCI)
CA47296 (NCI)
CA70907 (NCI)
SO Oncogene, (2001 Jul 5) 20 (30) 4041-9.
Journal code: 8711562. ISSN: 0950-9232.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200108
ED Entered STN: 20010813
Last Updated on STN: 20010903
Entered Medline: 20010830

L4 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:276207 BIOSIS
DN PREV200100276207
TI Amplification of the MDM2 gene, but not expression of ***splice*** variants of MDM2 mRNA, is associated with prognosis in soft tissue sarcoma.
AU Bartel, Frank [Reprint author]; Meye, Axel; Wuerl, Peter; Kappler, Matthias; Bache, Matthias; Lautenschlaeger, Christine; Gruenbaum, Ulrich; Schmidt, Hannelore; Taubert, Helge
CS Institute for Pathology, University of Halle-Wittenberg, Faculty of Medicine, Magdeburger Strasse 14, D-06097, Halle/Saale, Germany
frank.bartel@medizin.uni-halle.de
SO International Journal of Cancer, (20 May, 2001) Vol. 95, No. 3, pp. 168-175. print.
CODEN: IJCNAW. ISSN: 0020-7136.
DT Article
LA English
ED Entered STN: 13 Jun 2001
Last Updated on STN: 19 Feb 2002

L4 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:12949 BIOSIS
DN PREV200100012949
TI Alternatively ***spliced*** MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement.
AU Hori, Masao [Reprint author]; Shimazaki, Jiro; Inagawa, Satoshi; Itabashi, Masayuki; Hori, Mitsuo
CS Ibaraki Prefectural Central Hospital and Cancer Center, 6528 Koibuchi, Tomobe, Nishi-ibaraki-gun, Ibaraki, 309-1703, Japan
ms-hori@chubyoin.pref.ibaraki.jp
SO Pathology International, (October, 2000) Vol. 50, No. 10, pp. 786-792. print.
ISSN: 1320-5463.
DT Article
LA English
ED Entered STN: 27 Dec 2000
Last Updated on STN: 27 Dec 2000

=> d 1-5 ab

L4 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
AB The protein MDM2 coded by the ***human*** homologue of ***mouse*** ***double*** ***minute*** -2 (mdm2) gene frequently overexpresses in malignant human breast and other tumors. Artificial amplification of mouse mdm2 gene derived from a transformed murine cell line enhances tumorigenic potential of murine cells. These evidences suggest oncogenic properties of human or mouse MDM2. The tumorigenic property of MDM2 is not unexpected as MDM2 can inactivate several functions of the tumor suppressor p53. The protein also interacts with several cell cycle

regulatory proteins that may contribute to its tumorigenic ability. Several ***spliced*** forms of MDM2 have been detected in cells that overexpress MDM2. The function of the proteins coded by these ***spliced*** forms is not well understood. Overexpression of full-length MDM2 from its cDNA arrests G1 to S phase transition of normal human or murine cells. Elimination of the growth inhibitory domains of the oncoprotein induces tumorigenesis. Some cancer-derived cell lines are partially insensitive to MDM2-mediated growth arrest. Normal cells can induce MDM2 in response to oncogenic challenges such as UV irradiation or estrogen treatment. Normal cells may induce full-length MDM2 in response to oncogenic challenges to protect against premature cell cycle progression. If the oncoprotein is defective in growth arrest or if the cells are insensitive to MDM2 mediated growth arrest, premature progression of cell cycle may lead to tumorigenesis. Elucidation of the growth regulatory functions of MDM2 may help develop new drug design for cancer treatment.

L4 ANSWER 2 OF 5 MEDLINE on STN DUPLICATE 2
AB To evaluate the significance of ***murine*** ***double*** ***minute*** 2 (MDM2) oncoprotein in ***human*** breast cancer as a nuclear-cytoplasmic shuttling protein, an estrogen receptor (ER) alpha regulator, and a prognostic marker and to study how MDM2 is overexpressed, we investigated its status in tissue samples and examined the correlation between overexpression and MDM2 gene abnormalities, status, and clinicopathological parameters. We detected MDM2 oncoprotein in both nucleus and cytoplasm by frozen-section immunohistochemistry. There was a significant correlation between MDM2 overexpression and low-grade nuclear atypia, absence of lymph node involvement, and increased levels of ER alpha protein. Our molecular assays found no point mutations in Ser17, but there was a correlation between MDM2 overexpression and the lack of ***splice*** variant mRNAs. These results suggest that the distribution of MDM2 reflects its nuclear-cytoplasmic shuttling ability; that interaction between p53 and MDM2 for tumor progression is not enhanced by point mutations at codon 17; and that the expression of MDM2 ***splice*** variants is a reason for the lack of its overexpression. MDM2 overexpression correlates with favorable prognostic parameters. A decreased level of MDM2 will lead to a deviation from the ER alpha signaling pathway.

L4 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 3
AB The ***human*** counterpart hdm2 of the ***murine*** ***double*** - ***minute*** 2 (mdm2) gene encodes a 90-kD protein (HDM2) that inhibits the function of the p53 tumor suppressor. Hdm2 is amplified in approximately 30% of sarcomas, leading to overproduction of HDM2 and inactivation of p53. Using immunohistochemistry to screen a panel of human tumors for HDM2 overproduction, we detected high levels of HDM2 in the cytoplasm in 25% of lung tumors as opposed to its normal localization in the nucleus. These samples contained full-length hdm2 and several alternate- ***splice*** forms of hdm2 mRNA. Sequence analysis revealed deletions in the alternate- ***splice*** forms of the p53 binding domain and absence of a nuclear localization signal. In transient transfection assays, one of the alternate- ***splice*** forms, HDM2(ALT1), bound and sequestered full-length HDM2 in the cytoplasm. In addition, the binding of HDM2(ALT1) to HDM2 inhibited the interaction of HDM2 with p53, thus enhancing p53 transcriptional activity. These data suggest the existence of another level of regulation of HDM2 which increases the activity of p53.

L4 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AB The MDM2 gene encodes a 90-kDa oncoprotein that is overexpressed in several human carcinomas, osteosarcomas, gliomas and soft tissue sarcomas (STSs). This overexpression is the result of several mechanisms, for example, enhanced transcription or translation, gene amplification and alternative splicing. We found that 19 of 67 (28.4%) STS specimens contained an amplified MDM2 gene. The amplification was more likely to be present in grade I tumors than in grade 2 or 3 tumors (58% of grade I tumors vs. 15% of grade 2 or 3 tumors, p = 0.001, chi2 test). Furthermore, patients with tumors that contained an amplified MDM2 gene had a survival estimate (87 months) that was longer than that of patients with tumors that lacked an amplified gene (40 months; p = 0.02, log-rank test). Alternatively and aberrantly ***spliced*** MDM2 mRNAs were detected in human STSs by a highly sensitive reverse transcription-polymerase chain reaction method. Of 71 tumor samples, 38 (54%) showed evidence of the ***spliced*** forms, which included MDM2-A, MDM2-B and several variants exclusively expressed in STSs. A common feature of all forms was the absence of the MDM2 N-terminal region, which includes the

TP53-binding region. Furthermore, the presence of the ***spliced*** forms was associated with elevated levels of TP53 (p = 0.01, chi2 test). Although the presence of ***spliced*** forms was associated with late-stage tumor phenotypes (p = 0.05, chi2 test), we observed no relationship between the presence of ***splice*** variants and patient outcome.

L4 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AB Several short forms of alternatively ***spliced*** Murine double minute 2 (MDM2) transcripts have recently been shown to correlate with high-grade malignancy in a number of human tumors. We examined the frequency of ***splice*** variants and their correlation with clinicopathological features in 60 cases of human breast cancer. Seven short forms coexpressed with wild-type mRNA were detected by nested RT-PCR. Sequencing of all the MDM2 variants demonstrated mRNA splicing which disrupted not only the conserved p53-binding domain but also, further towards the carboxyterminus, the conserved nuclear localization sequence and/or the acidic and zinc finger domains. There was no significant correlation between the coexpression of ***splice*** variants and tumor size, histologic type or hormone (estrogen and progesterone) receptor status. However, cases with ***spliced*** MDM2 transcripts tended to be of a more aggressive type with axillary lymph node involvement and extensive necrosis in the tumors. Although the functional significance of MDM2 variants remains obscure, we anticipate that these variants will be confirmed as a novel prognostic marker in human breast cancer.

=> s l4 and junction
L5 0 L4 AND JUNCTION

=> dis his

(FILE 'HOME' ENTERED AT 18:46:04 ON 24 NOV 2004)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 18:46:15 ON 24 NOV 2004
L1 1054 S (MOUSE OR MURINE)(2W) DOUBLE MINUTE
L2 136 S L1 (5A) HUMAN
L3 17 S L2 AND SPLICE?
L4 5 DUP REM L3 (12 DUPLICATES REMOVED)
L5 0 S L4 AND JUNCTION

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.21	27.42

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:55:29 ON 24 NOV 2004